Microparticulate Varenicline Citrate
Patent No. EP3785702 (titled "Microparticulate Varenicline Citrate") was filed by Alfred E Tiefenbacher on Mar 6, 2020. The application was issued on Jul 20, 2022.
Patent Summary
A new form of varenicline citrate, a drug used to treat nicotine addiction, that provides consistent properties and uniform dosing. The new form is a microparticulate hydrate of varenicline citrate, obtained by precipitating the salt from a solvent mixture. This avoids the need for micronization to achieve uniformity, as the microparticles form spontaneously. The new form has a consistent water content, around 1.5-5%, and X-ray diffraction pattern. It enables uniform batch, blend, and dosage form properties for varenicline citrate, simplifying manufacture and dosing consistency.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3785702
- Application Number
- EP20161476A
- Filing Date
- Mar 6, 2020
- Status
- Revoked
- Jan 24, 2025
- Publication Date
- Jul 20, 2022
- External Links
- Slate, Register , Google Patents